
    
      The specific aims include:

      Primary aims:

        1. Examine the efficacy of salsalate (3g/day) in improving positive and negative symptoms
           as measured by the Positive and Negative Syndrome Scale (PANSS) and the Scale for
           Assessment of Negative Symptoms (SANS).

        2. Examine the efficacy of salsalate in improving cognition as measured by the Measurement
           and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) composite score.

      Secondary aims:

      1. Examine salsalate's effects on inflammatory markers such as high sensitivity C-reactive
      protein (hs-CRP), TNF-Î± and IL-6.
    
  